Neurodevelopmental outcomes of infants with bronchopulmonary dysplasia
Corresponding Author
Sara B. DeMauro MD, MSCE
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Children's Hospital of Philadelphia—Roberts Center for Pediatric Research, Philadelphia, Pennsylvania, USA
Correspondence Sara B. DeMauro, MD, MSCE, Children's Hospital of Philadelphia—Roberts Center for Pediatric Research, 2716 South St, Philadelphia, PA 19146, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Sara B. DeMauro MD, MSCE
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Children's Hospital of Philadelphia—Roberts Center for Pediatric Research, Philadelphia, Pennsylvania, USA
Correspondence Sara B. DeMauro, MD, MSCE, Children's Hospital of Philadelphia—Roberts Center for Pediatric Research, 2716 South St, Philadelphia, PA 19146, USA.
Email: [email protected]
Search for more papers by this authorAbstract
Preterm infants with bronchopulmonary dysplasia (BPD), and particularly those who develop the most severe forms of chronic lung disease during the neonatal period, are at high risk for poor developmental outcomes throughout childhood. Infants who require mechanical ventilation at 36 weeks post-menstrual age have significantly increased odds for cerebral palsy, developmental delay at 2 years, and poor academic achievement and low intelligence quotient in adolescence. Over the past several decades, many therapies and care strategies, including steroids, continuous positive airway pressure, surfactant, and other medications have been introduced into clinical practice. These approaches have changed the epidemiology of BPD in very preterm infants. However, BPD remains common and strongly associated with poor development throughout childhood. Only caffeine has been proven to reduce BPD and improve childhood developmental outcomes. In future research, it will be essential to better understand the developmental sequelae of BPD beyond school age and to test interventions to improve developmental trajectories in this population. As new management strategies for BPD are developed, it will be essential to rigorously evaluate both short-term and long-term effects before they are introduced into routine neonatal practice.
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
REFERENCES
- 1van Katwyk S, Augustine S, Thebaud B, Thavorn K. Lifetime patient outcomes and healthcare utilization for Bronchopulmonary dysplasia (BPD) and extreme preterm infants: a microsimulation study. BMC Pediatr. 2020; 20(1): 136.
- 2Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: Final Data for 2018. Natl Vital Stat Rep. 2019; 68(13): 1-47.
- 3Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA 2015; 314(10): 1039-1051.
- 4Dubner SE, Dodson CK, Marchman VA, Ben-Shachar M, Feldman HM, Travis KE. White matter microstructure and cognitive outcomes in relation to neonatal inflammation in 6-year-old children born preterm. Neuroimage Clin. 2019; 23:101832.
- 5Ratner V, Kishkurno SV, Slinko SK, et al. The contribution of intermittent hypoxemia to late neurological handicap in mice with hyperoxia-induced lung injury. Neonatology 2007; 92(1): 50-58.
- 6Lee JM, Choi YH, Hong J, et al. Bronchopulmonary dysplasia is associated with altered brain volumes and white matter microstructure in preterm infants. Neonatology 2019; 116(2): 163-170.
- 7Grelli KN, Keller RL, Rogers EE, et al. Bronchopulmonary dysplasia precursors influence risk of white matter injury and adverse neurodevelopmental outcome in preterm infants [published online ahead of print September 16, 2020]. Pediatr Res. https://doi.org/10.1038/s41390-020-01162-2
- 8Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics. 2000; 105(6): 1216-1226.
- 9Hack M, Wilson-Costello D, Friedman H, Taylor GH, Schluchter M, Fanaroff AA. Neurodevelopment and predictors of outcomes of children with birth weights of less than 1000 g: 1992–1995. Arch Pediatr Adolesc Med. 2000; 154(7): 725-731.
- 10Gregoire MC, Lefebvre F, Glorieux J. Health and developmental outcomes at 18 months in very preterm infants with bronchopulmonary dysplasia. Pediatrics. 1998; 101(5): 856-860.
- 11Skidmore MD, Rivers A, Hack M. Increased risk of cerebral palsy among very low-birthweight infants with chronic lung disease. Dev Med Child Neurol. 1990; 32(4): 325-332.
- 12Perlman JM, Volpe JJ. Movement disorder of premature infants with severe bronchopulmonary dysplasia: a new syndrome. Pediatrics. 1989; 84(2): 215-218.
- 13Singer L, Yamashita T, Lilien L, Collin M, Baley J. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics. 1997; 100(6): 987-993.
- 14Taylor HG, Klein N, Schatschneider C, Hack M. Predictors of early school age outcomes in very low birth weight children. J Dev Behav Pediatr. 1998; 19(4): 235-243.
- 15Vohr BR, Coll CG, Lobato D, Yunis KA, O'Dea C, Oh W. Neurodevelopmental and medical status of low-birthweight survivors of bronchopulmonary dysplasia at 10 to 12 years of age. Dev Med Child Neurol. 1991; 33(8): 690-697.
- 16Robertson CM, Etches PC, Goldson E, Kyle JM. Eight-year school performance, neurodevelopmental, and growth outcome of neonates with bronchopulmonary dysplasia: a comparative study. Pediatrics. 1992; 89(3): 365-372.
- 17Hughes CA, O'Gorman LA, Shyr Y, Schork MA, Bozynski ME, McCormick MC. Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. J Dev Behav Pediatr. 1999; 20(1): 1-8.
- 18Short EJ, Klein NK, Lewis BA, et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 2003; 112(5):e359.
- 19Majnemer A, Riley P, Shevell M, Birnbaum R, Greenstone H, Coates AL. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Dev Med Child Neurol. 2000; 42(1): 53-60.
- 20Schmidt B, Roberts RS, Davis PG, et al. Prediction of late death or disability at age 5 years using a count of 3 neonatal morbidities in very low birth weight infants. J Pediatr. 2015; 167(5): 982-986.
- 21Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003; 289(9): 1124-1129.
- 22Drummond D, Hadchouel A, Torchin H, et al. Educational and health outcomes associated with bronchopulmonary dysplasia in 15-year-olds born preterm. PLOS One 2019; 14(9):e0222286.
- 23Sriram S, Schreiber MD, Msall ME, et al. Cognitive development and quality of life associated with BPD in 10-year-olds born preterm. Pediatrics. 2018; 141(6):e20172719.
- 24Twilhaar ES, Wade RM, de Kieviet JF, van Goudoever JB, van Elburg RM, Oosterlaan J. Cognitive outcomes of children born extremely or very preterm since the 1990s and associated risk factors: a meta-analysis and meta-regression. JAMA Pediatr. 2018; 172(4): 361-367.
- 25Gou X, Yang L, Pan L, Xiao D. Association between bronchopulmonary dysplasia and cerebral palsy in children: a meta-analysis. BMJ Open. 2018; 8(9):e020735.
- 26de Mello RR, Rodrigues Reis AB, da Silva KS. Cognitive performance of premature infants: association between bronchopulmonary dysplasia and cognitive skills. Cross-sectional study. Sao Paulo Med J. 2017; 135(4): 383-390.
- 27Simpson SJ, Turkovic L, Wilson AC, et al. Lung function trajectories throughout childhood in survivors of very preterm birth: a longitudinal cohort study. Lancet Child Adolesc Health. 2018; 2(5): 350-359.
- 28Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116(6): 1353-1360.
- 29Short EJ, Kirchner HL, Asaad GR, et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med. 2007; 161(11): 1082-1087.
- 30Jensen EA, Dysart K, Gantz MG, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. an evidence-based approach. Am J Respir Crit Care Med. 2019; 200(6): 751-759.
- 31Walsh MC, Morris BH, Wrage LA, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr. 2005; 146(6): 798-804.
- 32Zhang H, Dysart K, Kendrick DE, et al. Prolonged respiratory support of any type impacts outcomes of extremely low birth weight infants. Pediatr Pulmonol. 2018; 53(10): 1447-1455.
- 33DeMauro SB, D'Agostino JA, Bann C, et al. Developmental outcomes of very preterm infants with tracheostomies. J Pediatr. 2014; 164(6): 1303-1310.
- 34Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017; 3:CD004454.
- 35Raikkonen K, Gissler M, Kajantie E. Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children. JAMA. 2020; 323(19): 1924-1933.
- 36DeMauro SB. Antenatal corticosteroids—too much of a good thing? JAMA. 2020; 323(19): 1910-1912.
- 37Schmolzer GM, Kumar M, Pichler G, Aziz K, O'Reilly M, Cheung PY. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ. 2013; 347: f5980.
- 38Vaucher YE, Peralta-Carcelen M, Finer NN, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med. 2012; 367(26): 2495-2504.
- 39Bruschettini M, O'Donnell CP, Davis PG, Morley CJ, Moja L, Calevo MG. Sustained versus standard inflations during neonatal resuscitation to prevent mortality and improve respiratory outcomes. Cochrane Database Syst Rev. 2020; 3:CD004953.
- 40Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2012; 11:CD001456.
- 41Sinn JK, Ward MC, Henderson-Smart DJ. Developmental outcome of preterm infants after surfactant therapy: systematic review of randomized controlled trials. J Paediatr Child Health. 2002; 38(6): 597-600.
- 42Panza R, Laforgia N, Bellos I, Pandita A. Systematic review found that using thin catheters to deliver surfactant to preterm neonates was associated with reduced bronchopulmonary dysplasia and mechanical ventilation. Acta Paediatr. 2020; 109(11): 2219-2225.
- 43Askie LM, Darlow BA, Finer N, et al. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective meta-analysis collaboration. JAMA 2018; 319(21): 2190-2201.
- 44Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 1999; 340(25): 1962-1968.
- 45Ambalavanan N, Carlo WA, Bobashev G, et al. Prediction of death for extremely low birth weight neonates. Pediatrics 2005; 116(6): 1367-1373.
- 46Schmidt B, Roberts RS, Anderson PJ, et al. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: an 11-year follow-up of the CAP randomized clinical trial. JAMA Pediatr. 2017; 171(6): 564-572.
- 47Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006; 354(20): 2112-2121.
- 48Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007; 357(19): 1893-1902.
- 49Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012; 307(3): 275-282.
- 50Doyle LW, Ranganathan S, Cheong JLY. Neonatal caffeine treatment and respiratory function at 11 years in children under 1,251 g at birth. Am J Respir Crit Care Med. 2017; 196(10): 1318-1324.
- 51Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 10:CD001146.
- 52Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009; 123(1): 367-377.
- 53Harmon HM, Jensen EA, Tan S, et al. Timing of postnatal steroids for bronchopulmonary dysplasia: association with pulmonary and neurodevelopmental outcomes. J Perinatol. 2020; 40(4): 616-627.
- 54Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr. 2014; 165(6): 1258-1260.
- 55Shah VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database Syst Rev. 2017; 1:CD001969.
- 56Onland W, Offringa M, van Kaam A. Late (>/=7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 8:CD002311.
- 57Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and meta-analysis. Pediatr Pulmonol. 2017; 52(7): 968-975.
- 58Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics 2008; 121(5): e1310-e1318.
- 59Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. Pediatrics. 2006; 117(4): 1253-1261.
- 60Clark RH, Huckaby JL, Kueser TJ, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol. 2003; 23(4): 300-303.
- 61Milanesi BG, Lima PA, Villela LD, et al. Assessment of early nutritional intake in preterm infants with bronchopulmonary dysplasia: a cohort study [published online ahead of print January 3, 2021]. Eur J Pediatr. https://doi.org/10.1007/s00431-020-03912-0
- 62Poindexter BB, Martin CR. Impact of nutrition on bronchopulmonary dysplasia. Clin Perinatol. 2015; 42(4): 797-806.
- 63Lagatta JM, Clark RH, Brousseau DC, Hoffmann RG, Spitzer AR. Varying patterns of home oxygen use in infants at 23–43 weeks' gestation discharged from United States neonatal intensive care units. J Pediatr. 2013; 163(4): 976-982.
- 64DeMauro SB, Jensen EA, Bann CM, et al. Home oxygen and 2-year outcomes of preterm infants with bronchopulmonary dysplasia. Pediatrics. 2019; 143(5):e20182956.
- 65Rhein L, White H, Simoneau T, et al. Transmitted home oximetry and duration of home oxygen in premature infants. Pediatrics. 2020; 146(2):e20200079.
- 66DeMauro SB. Recorded continuous oximetry improves postdischarge management of bronchopulmonary dysplasia. Pediatrics. 2020; 146(2):e2020002774.
- 67Luo J, Shepard S, Nilan K, et al. Improved growth and developmental activity post tracheostomy in preterm infants with severe BPD. Pediatr Pulmonol. 2018; 53(9): 1237-1244.
- 68Spittle A, Orton J, Anderson PJ, Boyd R, Doyle LW. Early developmental intervention programmes provided post hospital discharge to prevent motor and cognitive impairment in preterm infants. Cochrane Database Syst Rev. 2015; 11:CD005495.
- 69Novak I, Morgan C, Adde L, et al. Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA Pediatr. 2017; 171(9): 897-907.
- 70Shepherd EG, Knupp AM, Welty SE, Susey KM, Gardner WP, Gest AL. An interdisciplinary bronchopulmonary dysplasia program is associated with improved neurodevelopmental outcomes and fewer rehospitalizations. J Perinatol. 2012; 32(1): 33-38.